Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, WHWK, TNGX, STRO, AVBP, and represent 54.34% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: AVBP (+$7.6M), FDMT (+$6.8M), WHWK (+$5.8M), Avalyn Pharma, ARTV, AVTX, DSGN, CTNM, TSHA, MLTX.
- Started 5 new stock positions in CTNM, FDMT, ARTV, Avalyn Pharma, AVBP.
- Reduced shares in these 10 stocks: IDYA (-$162M), TERN (-$26M), OCS, RVMD, 4d Molecular Therapeutics In, ERAS, TNGX, DRUG, TRDA, PRAX.
- Sold out of its positions in TRDA, 4d Molecular Therapeutics In, IDYA, MAZE, RVMD, TERN, UNCY, OCS.
- Acuta Capital Partners was a net seller of stock by $-170M.
- Acuta Capital Partners has $144M in assets under management (AUM), dropping by -52.31%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 23 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 19.3 | $28M | -2% | 83k | 334.79 |
|
| Aadi Bioscience (WHWK) | 15.0 | $22M | +37% | 4.7M | 4.58 |
|
| Tango Therapeutics (TNGX) | 8.5 | $12M | -11% | 391k | 31.26 |
|
| Sutro Biopharma (STRO) | 6.3 | $9.0M | 270k | 33.20 |
|
|
| Arrivent Biopharma (AVBP) | 5.3 | $7.6M | NEW | 219k | 34.74 |
|
| 4d Molecular Therapeutics In (FDMT) | 4.7 | $6.8M | NEW | 508k | 13.30 |
|
| Bright Minds Biosciences Com New (DRUG) | 4.5 | $6.5M | -17% | 93k | 70.20 |
|
| Ocular Therapeutix (OCUL) | 3.6 | $5.2M | -10% | 533k | 9.82 |
|
| Erasca (ERAS) | 3.4 | $4.9M | -25% | 265k | 18.32 |
|
| Surrozen Com New (SRZN) | 3.1 | $4.5M | 173k | 25.95 |
|
|
| Argen Se - Sponsored Adr (ARGX) | 3.0 | $4.4M | 4.7k | 927.77 |
|
|
| Moonlake Immunotherapeutics Class Ord A (MLTX) | 2.9 | $4.2M | +12% | 216k | 19.47 |
|
| Design Therapeutics (DSGN) | 2.8 | $4.1M | +93% | 283k | 14.47 |
|
| Minerva Neurosciences Com New (NERV) | 2.7 | $3.9M | 710k | 5.55 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 2.7 | $3.8M | +27% | 562k | 6.81 |
|
| Avalyn Pharma Com Shs | 2.6 | $3.8M | NEW | 115k | 32.92 |
|
| Avalo Therapeutics Com New (AVTX) | 2.4 | $3.4M | +206% | 186k | 18.48 |
|
| Amylyx Pharmaceuticals (AMLX) | 2.1 | $3.0M | +11% | 168k | 17.96 |
|
| Artiva Biotherapeutics (ARTV) | 1.8 | $2.5M | NEW | 260k | 9.70 |
|
| Compass Therapeutics (CMPX) | 0.9 | $1.3M | -29% | 595k | 2.19 |
|
| United Therapeutics Corporation (UTHR) | 0.8 | $1.2M | 2.2k | 541.83 |
|
|
| Contineum Therapeutics Inc-a Cl A (CTNM) | 0.7 | $1.0M | NEW | 63k | 16.39 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.7 | $939k | 29k | 32.45 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2026 Q2 filed Aug. 14, 2026
- Acuta Capital Partners 2026 Q1 filed May 15, 2026
- Acuta Capital Partners 2025 Q4 filed Feb. 17, 2026
- Acuta Capital Partners 2025 Q3 filed Nov. 14, 2025
- Acuta Capital Partners 2025 Q2 filed Aug. 14, 2025
- Acuta Capital Partners 2025 Q1 filed May 15, 2025
- Acuta Capital Partners 2024 Q4 filed Feb. 14, 2025
- Acuta Capital Partners 2024 Q3 filed Nov. 14, 2024
- Acuta Capital Partners 2024 Q2 filed Aug. 14, 2024
- Acuta Capital Partners 2024 Q1 filed May 15, 2024
- Acuta Capital Partners 2023 Q4 filed Feb. 14, 2024
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022